Haemonetics stock surges 16% on CSL Plasma supply deal
Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.
How this was made
The 30-second read
Why it matters
The immediate market reaction suggests investors value potential expansion in plasma collection equipment and consumables, but management is not updating fiscal 2027 guidance due to implementation uncertainty. The next catalyst is the planned update during the second fiscal quarter earnings call in November 2026.
Market read
A concrete commercial contract drove a large same-day move, but guidance remains unchanged, implying traders will wait for rollout details before repricing long-term earnings.
What to watch
Traders may be over-weighting the headline move; the key variable is whether CSL’s center transitions are large and fast enough to change the company’s 2027 earnings trajectory.
Background
Haemonetics announced a non-exclusive supply agreement signed Aug 14, 2026 with CSL Plasma for NexSys PCS devices using Persona PLUS technology and related disposables in the U.S.
Ticker impact
Haemonetics shares jumped 16.3% after announcing a non-exclusive U.S. supply agreement with CSL Plasma for NexSys PCS devices and disposables.
Likely supports continued momentum in the near term, but follow-through may depend on how CSL rollout scope and timing are clarified on the next earnings call.
The article provides a fresh contract catalyst and explains why guidance is unchanged, signaling upside optionality with execution uncertainty.
Market effects
Could be read as incremental demand signal for plasma collection device and consumables suppliers, though the non-exclusive structure tempers sector-wide read-through.
U.S. plasma collection center transition focus may concentrate impact in U.S. healthcare supply chains.
Limited, since the agreement is described as U.S.-only with no stated international expansion.
Counterpoint
The absence of minimum purchase commitments and unspecified rollout timing may mean the deal is more strategic than financially material for fiscal 2027.
Key entities
- companyHaemonetics Corporation
Subject of the article, with shares up 16.3% on the supply agreement announcement.
- companyCSL Plasma Inc.
Counterparty expected to transition some U.S. plasma collection centers to Haemonetics devices and disposables.
- productNexSys PCS
Haemonetics plasma collection device platform referenced in the agreement.
- technologyPersona PLUS technology
Technology used with NexSys PCS devices under the supply agreement.
